M

Myomo Inc
AMEX:MYO

Watchlist Manager
Myomo Inc
AMEX:MYO
Watchlist
Price: 5.09 USD 6.04% Market Closed
Market Cap: 154m USD
Have any thoughts about
Myomo Inc?
Write Note

Myomo Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Myomo Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
M
Myomo Inc
AMEX:MYO
Other Long-Term Assets
$91.2k
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Other Long-Term Assets
$2.6B
CAGR 3-Years
10%
CAGR 5-Years
19%
CAGR 10-Years
18%
Boston Scientific Corp
NYSE:BSX
Other Long-Term Assets
$4.5B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
28%
Stryker Corp
NYSE:SYK
Other Long-Term Assets
$3.9B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
18%
Abbott Laboratories
NYSE:ABT
Other Long-Term Assets
$7.7B
CAGR 3-Years
24%
CAGR 5-Years
27%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Other Long-Term Assets
$1.6B
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
28%
No Stocks Found

Myomo Inc
Glance View

Market Cap
154m USD
Industry
Health Care

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.

MYO Intrinsic Value
3.7 USD
Overvaluation 27%
Intrinsic Value
Price
M

See Also

What is Myomo Inc's Other Long-Term Assets?
Other Long-Term Assets
91.2k USD

Based on the financial report for Sep 30, 2024, Myomo Inc's Other Long-Term Assets amounts to 91.2k USD.

What is Myomo Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-15%

Over the last year, the Other Long-Term Assets growth was 0%.

Back to Top